April 13, 2022
The study covered in this summary was published on medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaways Novel reduced-dose intranasal oxytocin […]
April 12, 2022
Scientists believe they have developed a drug that neutralizes a neurotoxic chemical in the brain that triggers the degenerative process leading to Alzheimer’s disease (AD). The […]
April 12, 2022
The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. Key Takeaways Patients with glioblastoma (GBM) […]
April 12, 2022
SEATTLE – An update from a phase 2 study – core and open-label extension – of lecanemab in Alzheimer’s disease showed that the antibody reduced amyloid […]
April 11, 2022
SEATTLE – Multiple sclerosis (MS), sometimes thought of as primarily affecting Whites, is also common among Hispanic and Black people. These populations often have more severe disease, likely driven […]
April 11, 2022
The study covered in this summary was published on MedRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaways White matter aberration appears […]
April 11, 2022
An experimental drug that combines fixed doses of extended-release (ER) formulations of existing medications can significantly reduce symptoms in patients with untreated early-stage Parkinson’s disease (PD), […]
April 11, 2022
This article was originally published in German on Medscape. Shift work is associated with poor working memory and slower mental processing speed. This is the outcome […]
April 8, 2022
SEATTLE — A novel therapy for ataxia telangiectasia that delivers dexamethasone sodium phosphate (DSP) through autologous red blood cells has shown promise in a phase 3 clinical trial. […]